Search
for
Sort by
Research 301–330 of 777
- Harnessing neuroendocrine controls of keratin expression: A new therapeutic strategy for skin diseases?
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- 600 Impact of baricitinib on work productivity and indirect costs in adult patients with atopic dermatitis: A meta-analysis of clinical trials
- Clinical response to oral tofacitinib in pediatric patients with alopecia areata
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Hair follicle targeting via gelatin coated transferosomes loaded with tofacitinib citrate for enhanced treatment of alopecia areata: Clinical evaluation of alopecia areata patients
- Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
- Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
- Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- Baricitinib-loaded separable microneedle array patch (S-MAP) based on hyaluronic acid for alopecia areata therapy
- Tissue Retinol‐Binding Protein 4 Expression and Its Genetic Variants (rs3758539) in Patients With Severe and Treatment‐Refractory Alopecia Areata: Association With Response to Baricitinib
- Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
- A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
- Mesenchymal Stem Cell Therapy in Alopecia Areata: Visual and Molecular Evidence from a Mouse Model
- Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
- Evaluating the Causal Relationship Between Human Blood Metabolites and the Susceptibility to Alopecia Areata
- Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
- Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
- Gut microbiome, metabolome and alopecia areata
- Evaluation of Olive Oil-Based Formulations Loaded with Baricitinib for Topical Treatment of Alopecia Areata
- Treatments for alopecia areata: a network meta-analysis
- Comprehensive single-cell transcriptomic profiling of the scalp from patients with moderate-to-severe alopecia areata
- Exploring the Complexities of TGF-beta Signaling in Keloids: Beyond the Classical Smad Pathway
- Extracellular vesicles from IFN-γ-primed mesenchymal stem cells repress atopic dermatitis in mice
- Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy